Metformin-Based Combination Approaches for Triple-Negative Breast Cancer DOI Creative Commons
Zaid Sirhan,

Aya Abu Nada,

Nadeen Anabtawi

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(5), С. 558 - 558

Опубликована: Апрель 24, 2025

Numerous anti-diabetic medications, including metformin, have been explored for their anticancer effects because of the substantial correlation between diabetes and cancer incidence. Metformin has recently gained interest its against malignancies such as breast cancer, one leading causes death among women worldwide. The cancer-related characteristics cell proliferation, invasion, migration, apoptosis are all targeted by metformin. Among patients, triple-negative (TNBC) is linked to an increased risk early recurrence metastases poor prognosis. In addition, TNBC fewer treatment options compared other subtypes it lacks hormone receptors human epidermal growth factor receptor 2 (HER2), often develops resistance available options. current review highlights recent updates on mechanistic insights efficacy metformin metformin-based approaches TNBC. We logically discuss experimental evidence from in vitro vivo studies exploring metformin’s metabolic pathways, then combination with therapeutic agents, targeting signaling enhance effects. also present clinical that underscore beneficial outcomes or agents patients.

Язык: Английский

G-protein coupled receptors in metabolic reprogramming and cancer DOI
Songyeon Ahn, Benny Abraham Kaipparettu

Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown, С. 108849 - 108849

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Metformin-Based Combination Approaches for Triple-Negative Breast Cancer DOI Creative Commons
Zaid Sirhan,

Aya Abu Nada,

Nadeen Anabtawi

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(5), С. 558 - 558

Опубликована: Апрель 24, 2025

Numerous anti-diabetic medications, including metformin, have been explored for their anticancer effects because of the substantial correlation between diabetes and cancer incidence. Metformin has recently gained interest its against malignancies such as breast cancer, one leading causes death among women worldwide. The cancer-related characteristics cell proliferation, invasion, migration, apoptosis are all targeted by metformin. Among patients, triple-negative (TNBC) is linked to an increased risk early recurrence metastases poor prognosis. In addition, TNBC fewer treatment options compared other subtypes it lacks hormone receptors human epidermal growth factor receptor 2 (HER2), often develops resistance available options. current review highlights recent updates on mechanistic insights efficacy metformin metformin-based approaches TNBC. We logically discuss experimental evidence from in vitro vivo studies exploring metformin’s metabolic pathways, then combination with therapeutic agents, targeting signaling enhance effects. also present clinical that underscore beneficial outcomes or agents patients.

Язык: Английский

Процитировано

0